Edition:
United Kingdom

Chemed Corp (CHE.N)

CHE.N on New York Stock Exchange

328.77USD
18 Mar 2019
Change (% chg)

$2.39 (+0.73%)
Prev Close
$326.38
Open
$326.75
Day's High
$329.64
Day's Low
$326.61
Volume
27,879
Avg. Vol
34,773
52-wk High
$335.86
52-wk Low
$263.64

Latest Key Developments (Source: Significant Developments)

Chemed Corporation's Board Of Directors Authorizes An Additional $150 Mln For Stock Repurchase
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Chemed Corp ::CHEMED CORPORATION’S BOARD OF DIRECTORS AUTHORIZES AN ADDITIONAL $150 MILLION FOR STOCK REPURCHASE.CHEMED - REPURCHASES WILL BE FUNDED THROUGH CASH GENERATED FROM OPERATIONS AS WELL AS UTILIZATION OF ITS REVOLVING CREDIT FACILITY.CHEMED - SHARE REPURCHASES WILL BE FUNDED THROUGH COMBINATION OF CASH GENERATED FROM OPERATIONS, UTILIZATION OF ITS REVOLVING CREDIT FACILITY.  Full Article

Chemed Corporation Declares Quarterly Dividend Of 30 Cents
Friday, 22 Feb 2019 

Chemed Corp ::CHEMED CORPORATION DECLARES QUARTERLY DIVIDEND OF 30 CENTS.  Full Article

Chemed Reports Fourth-Quarter 2018 Results
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - Chemed Corp ::CHEMED REPORTS FOURTH-QUARTER 2018 RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $3.35.Q4 GAAP EARNINGS PER SHARE $3.26.Q4 REVENUE $458 MILLION VERSUS REFINITIV IBES ESTIMATE OF $460.5 MILLION.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $12.65 TO $12.85 EXCLUDING ITEMS.Q4 EARNINGS PER SHARE ESTIMATE $3.26 -- REFINITIV IBES DATA.QTRLY REVENUE OF ROTO-ROOTER SEGMENT $151 MILLION, UP 10.6%.QTRLY REVENUE OF VITAS SEGMENT $307 MILLION, UP 5.0%.SEES REVENUE GROWTH FOR VITAS IN 2019, PRIOR TO MEDICARE CAP, ESTIMATED TO BE IN THE RANGE OF 5.5% TO 6.0%.ROTO-ROOTER IS FORECASTED TO ACHIEVE FULL-YEAR 2019 REVENUE GROWTH OF 9.0% TO 10.0%.FULL-YEAR 2019 ADJUSTED EARNINGS PER DILUTED SHARE ESTIMATED TO BE IN THE RANGE OF $12.65 TO $12.85.ROTO-ROOTER’S ADJUSTED EBITDA MARGIN FOR 2019 IS ESTIMATED AT 23.7%.FULL-YEAR ADJUSTED EBITDA MARGIN FOR VITAS IN 2019, PRIOR TO MEDICARE CAP, IS ESTIMATED TO BE 15.9%.CO ESTIMATING $10 MILLION FOR MEDICARE CAP BILLING LIMITATIONS IN 2019.  Full Article

Chemed Reports Third-Quarter 2018 Results
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Chemed Corp ::CHEMED REPORTS THIRD-QUARTER 2018 RESULTS - EARNINGS GUIDANCE INCREASED.Q3 ADJUSTED EARNINGS PER SHARE $3.07.Q3 GAAP EARNINGS PER SHARE $3.06.Q3 REVENUE $444 MILLION VERSUS I/B/E/S VIEW $445.2 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.80 TO $11.90 EXCLUDING ITEMS.Q3 EARNINGS PER SHARE VIEW $2.80 -- THOMSON REUTERS I/B/E/S.REVENUE GROWTH FOR VITAS IN 2018, PRIOR TO MEDICARE CAP, IS ESTIMATED TO BE IN RANGE OF 4.5% TO 5.0%.CURRENTLY ESTIMATING $1.3 MILLION FOR MEDICARE CAP BILLING LIMITATIONS IN Q4 OF 2018.SEES FULL-YEAR 2018 ADJUSTED EARNINGS PER DILUTED SHARE $11.80 TO $11.90.FY2018 EARNINGS PER SHARE VIEW $11.47, REVENUE VIEW $1.79 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Roto-Rooter Buys Five Northern California Franchises
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Chemed Corp ::ROTO-ROOTER BUYS FIVE NORTHERN CALIFORNIA FRANCHISES – ACQUISITION IS THE COMPANY’S LARGEST TO DATE.CHEMED CORP - TERMS OF TRANSACTION WERE NOT DISCLOSED.  Full Article

Chemed Q2 Adjusted Earnings Per Share $2.81
Wednesday, 25 Jul 2018 

Chemed Corp ::CHEMED REPORTS SECOND-QUARTER 2018 RESULTS - EARNINGS GUIDANCE INCREASED.Q2 ADJUSTED EARNINGS PER SHARE $2.81.Q2 GAAP EARNINGS PER SHARE $3.27.Q2 REVENUE $442 MILLION VERSUS I/B/E/S VIEW $434.3 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.35 TO $11.55 EXCLUDING ITEMS.Q2 EARNINGS PER SHARE VIEW $2.77 -- THOMSON REUTERS I/B/E/S.  Full Article

Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Chemed Corp ::Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​.Chemed Corp - ‍In connection with settlement, Vitas has also agreed to a corporate integrity agreement with office of inspector general​.Chemed - ‍Total settlement estimated at $85 million pre-tax & compares to $90 million pre-tax ($55.5 million after-tax) of estimated settlement cost recorded in Q2.Chemed Corp - ‍Company will fund the settlement with existing cash balances and its bank credit facility​.  Full Article

Chemed reports Q3 earnings per share $2.13
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Chemed Corp :Chemed reports third-quarter 2017 results.Sees FY 2017 adjusted earnings per share $8.35 to $8.40 excluding items.Q3 adjusted earnings per share $2.15.Q3 gaap earnings per share $2.13.Q3 earnings per share view $2.01 -- Thomson Reuters I/B/E/S.Chemed Corp - qtrly ‍revenue increased 6.3% to $417 million​.Q3 revenue view $413.8 million -- Thomson Reuters I/B/E/S.Chemed Corp qtrly ‍vitas net patient revenue of $289 million, an increase of 2.2%​.Chemed Corp - ‍roto-rooter is forecasted to achieve full-year 2017 revenue growth of 13% to 14%​.Chemed Corp - ‍adjusted ebitda margin for roto-rooter​ for 2017 is estimated at 22.5%.Chemed Corp - ‍revenue growth for vitas in 2017, prior to medicare cap, is estimated to be in range of 2% to 3%​.Chemed Corp - ‍admissions and average daily census for vitas in 2017 are estimated to expand approximately 2% to 3%​.Chemed Corp - ‍full-year 2017 adjusted ebitda margin for vitas, prior to medicare cap, is estimated to be 15.0% ​.  Full Article